top of page

University of Michigan forms chronic kidney disease consortium with pharma companies

The University of Michigan has established a chronic kidney disease (CKD) consortium with several pharmaceutical companies, including AstraZeneca and Eli Lilly and Company.

The Renal Pre-Competitive Consortium (RPC2) will develop and utilize large-scale data exploration to find new treatment targets for CKD.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page